Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Century Therapeutics, Inc. - Common Stock (NQ: IPSC )

1.100 +0.050 (+4.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4%
Via Benzinga
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
5 Analysts Assess Century Therapeutics: What You Need To Know
Via Benzinga
Century Therapeutics: Q4 Earnings Insights
Via Benzinga
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D... 
Via Benzinga
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational... 
From Century Therapeutics, Inc.
Via GlobeNewswire
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
While not on everyone’s radar, these enticing entities just might deliver the goods. 
Via InvestorPlace
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
IN8bio (NASDAQ: INAB) is a biotechnology company that specializes in developing novel therapies based on gamma-delta T cells. Its innovative technology focuses on harnessing the potential of these... 
Via Benzinga
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
Amidst fanfare for Nasdaq 100, U.S. small-cap stocks rally, with Russell 2000 index reaching levels not seen since Aug. 2022, 80% of stocks trading above 50-day MA, outperforming large caps &... 
Via Benzinga
Topics ETFs
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
From Century Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.